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Abstract
BACKGROUND: We have previously reported that
tissue expression levels of transcript AA454543 in
hepatocellular carcinoma (HCC) are significantly higher
than those of normal livers, livers with cirrhosis, and
livers with hepatitis. In addition, a higher level of tran-
script AA454543 in tumor tissues is associated with
poor prognosis. We aim to examine whether quanti-
tative measurement of preoperative plasma transcript
AA454543 can provide similar prognostic information.
PATIENTS AND METHODS: Blood samples were ob-
tained from 84 HCC patients before surgery. Real-time
quantitative reverse transcription–polymerase chain
reaction, using TaqMan system, was employed to
measure plasma transcript AA454543 and a-fetoprotein
(AFP) RNA levels. We assessed their prediction power
in prognosis using univariate and multivariate analy-
ses. RESULTS: High plasma transcript AA454543 RNA
levels were associated with poor overall survival (log-
rank test, P < .01). Patients with different plasma AFP
RNA levels revealed no difference in overall survival
(log-rank test, P = .88). By multivariate Cox regres-
sion analysis, plasma transcript AA454543 RNA level
(hazard ratio = 4.8,P < .01) and tumor stage (hazard ratio
= 1.7, P < .01) were determined to be independent risk
factors for the prediction of overall survival. CONCLU-
SION: Preoperative plasma transcript AA454543 RNA
level can provide prognostic information for HCC pa-
tients receiving curative partial hepatectomy.
Neoplasia (2006) 8, 696–701
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Introduction
Studies on the detection of cell-free nucleic acids in plasma
and serum have revealed potential in the initial diagnosis
and follow-up monitoring of a variety of cancers [1–3].
Different RNA targets have been used in diverse cancer
studies, and cytokeratin-19 frequently serves as a universal
marker for solid tumors of epithelial cell origin [4]. In addition,
studies on RNA targets of viral and cellular origins have been
reported, including studies on Epstein-Barr virus RNA in naso-
pharyngeal carcinoma, tyrosinase RNA in melanoma, catenin
RNA in adenoma and colorectal cancer, hnRNP B1 RNA in
lung cancer, and telomerase RNA in breast cancer, melanoma,
and thyroid cancer [5–10].
We have previously reported that the tissue expression of
transcript AA454543 (GenBank accession no. BC043195) was
specific for hepatocellular carcinoma (HCC), with a significantly
higher level in tumor tissues than in liver tissues adjacent
to tumors (comprising hepatitis and cirrhotic livers) and in
normal livers [11,12]. Furthermore, a higher level of transcript
AA454543 in tumor tissues was associated with aggressive
tumor features, including venous infiltration, microsatellite nod-
ules, late tumor stage, and poor overall survival [12]. Such as-
sociation could be explained by the biologic role of AA454543
in cell invasion. An increased level of transcript AA454543
might enhance the invasive ability of tumor cells, subsequently
resulting in venous infiltration and formation of microsatellite
nodules. Importantly, transcript AA45453 levels in tumor tis-
sues and tumor stage were independent prognostic factors for
overall survival [12]. The prognostic significance of transcript
AA454543 was first identified in our earlier cDNA microarray
dataset [11], in which data were validated by quantitative
reverse transcription–polymerase chain reaction (RT-PCR)
and then confirmed in a separate HCC sample set [12]. Thus,
quantitative assay of themolecularmarker transcript AA454543
in tumor tissues can provide general prognostic information
(two independent cohorts of HCC patients, and prediction is
independent of the assay method used).
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BRIEF ARTICLE
In the current study, we aim to investigate whether preop-
erative plasma RNA levels of transcript AA454543 can pro-
vide prognostic information. Plasma RNA levels of transcript
AA454543 and a-fetoprotein (AFP) were examined. Plasma
RNA data were compared with serum AFP protein data and
tumor stage to determine their prediction power on overall
survival. We report here that preoperative plasma transcript
AA454543 level is one of the independent prognostic factors
for HCC following partial hepatectomy.
Patients and Methods
Patients
The study protocol was approved by the Ethics Committee
of The University of Hong Kong, and informed consent was
obtained from the patients. Between October 1999 and
May 2004, 84 patients undergoing partial hepatectomy for
HCC at the Department of Surgery, The University of Hong
Kong, Queen Mary Hospital, were recruited for the current
study. The same team of surgeons performed all operations
throughout this period. All patients had been diagnosed
with primary HCC and have not received other treatments
before surgery. Clinicopathological data were prospectively
collected (Table 1). Overall survival was measured from the
date of surgery to the date of death due to liver cancer as
endpoint by the end of follow-up. Disease-free survival was
calculated from the date of surgery to the date of recurrence
and/or liver cancer death as endpoint by the end of follow-
up. Diagnosis of recurrence was based on typical imaging
findings in a contrast-enhanced computed tomography scan
and an increased serum AFP level. In case of uncertainty,
hepatic arteriography and post-Lipiodol computed tomog-
raphy scan were performed; when necessary, fine-needle
aspiration cytology was used for confirmation. Up to the date
of analysis, the median follow-up time was 25.4 months.
Isolation of Plasma RNA
Blood samples (10 ml each) were collected from each
patient before the operation. The blood samples collected
were stored at 4jC, and the plasma separated within
24 hours. The blood samples were centrifuged at 3000 rpm
for 20 minutes to separate the plasma. Parallel plasma sam-
ples that had been centrifuged once and twice were com-
pared, and theydid not reveal a significant difference in plasma
RNA levels, including 18S, AFP, and AA454543 in our pilot
study. Thereafter, including all plasma samples used in the
current study, the blood samples were centrifuged once.
Plasma specimens were stored at 70jC until use. Total
RNA was extracted using TRIZOL LS reagent (Invitrogen,
Carlsbad, CA). Briefly, 200 ml of plasma was added to 600 ml
of TRIZOL LS, mixed, incubated at room temperature for
5 minutes, and added to 160 ml of chloroform. After thorough
mixing, the mixture was centrifuged at 13,000 rpm for 30 min-
utes at 4jC. The aqueous phase (360 ml) on top was trans-
ferred to a clean tube, then added to 10 mg of glycogen and
400 ml of isopropanol. RNA was precipitated by centrifugation,
and RNA pellet was washed once with 75% ethanol. The RNA
pellet was then dissolved with 50 ml of diethylpyrocarbonate
(DEPC)–water for subsequent quantitative assays.
Real-Time Quantitative RT-PCR
Real-time quantitative RT-PCR was performed using an
ABI PRISM 7700 Sequence Detection System (Applied Bio-
systems, Foster City, CA), as described [12]. First-strand
cDNA was synthesized with 4.5 ml of total RNA in 50 ml of
reaction mixture using High-Capacity cDNA Achive kit (Ap-
plied Biosystems), following the manufacturer’s instructions.
The 5-ml first-strand cDNA was then used in each 25-ml
quantitative assay with 1 PCR buffer II; 5.5 mM MgCl2;
0.2 mM dATP, dCTP, and dGTP; 0.4 mM dUTP; and 0.625 U
of AmpliTaq Gold (Applied Biosystems, Foster City, CA). The
primers and probe for transcript AA454543 were AA454543-
F (5V-CAATCAGACAGGCTGCTT TTC TC-3V), AA454543-
R (5V-CTT CCT AAT TAA TGT TTG CAC CAT ATG-3V), and
AA454543-P (5V-6FAM AAC TCA TAG GTA ACA AAC ACA
AA-MGBNFQ-3V). The primers and probe for AFP RNA were
AFP-F (5V-ACT CCA GTA AAC CCT GGT GTT G-3V), AFP-R
(5V-ACATATGTTTCATCCACCACCAA-3V), andAFP-P (5V-
6FAMCAC TTC TTC ATATGCC-MGBNFQ-3V). The primers
and probe reagents for control ribosomal 18S were ready-
made reagents (Pre-Developed TaqMan Assay Reagents;
Applied Biosystems) and served as quality control for all
samples in all assays. Transcript quantification was per-
formed at least in duplicate for every sample. The PCR profile
for the quantitative assay included incubation at 95jC for
10 minutes and then 40 cycles of 95jC for 15 seconds and
60jC for 1 minute. The amplification plots of PCR were used
to determine the threshold cycle (CT), and the threshold line
was usually set at Rn = 0.1. The CT value represented the
PCR cycle at which an increase in reporter fluorescence
above a baseline signal could first be detected. Calibrator
Table 1. Clinicopathological Features of HCC.
HCC Features Total (n = 84)
Age in years [median (range)] 52 (24–79)
Gender
Male 72
Female 12
Tumor stage*
I and II 46
III and IV 38
Tumor size (cm) [median (range)] 11 (3–22)
Serum AFP level (ng/ml) [median (range)] 249.5 (1–1,043,700)
HBsAg
Positive 74
Negative 10
Underlying liver disease
Noncirrhosis 59
Cirrhosis 25
Disease recurrence
With 50
Without 34
Disease mortality
Death 31
Living 53
*Tumor stage according to the American Joint Committee on Cancer Staging
Manual [15].
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control was the sample at which the transcript amount was
at the baseline level of the sample series. The relative amount
of plasma RNA, after normalization with the calibrator and
after adjustment for plate-to-plate variation, presented the
fold difference (log 2 base scale) relative to baseline level.
The relative amount of plasma transcript AA454543 is
expressed as dCT(AA454543), where dCT(AA454543 test
sample) = [CT(AA454543 calibrator)  CT(AA454543 test
sample)]. Similarly, the relative amount of plasmaAFPmRNA
is expressed as dCT(AFP), where dCT(AFP test sample) =
[CT(AFP calibrator)  CT(AFP test sample)].
Study Report
We followed the recommendation for tumor marker prog-
nostic studies by the National Cancer Institute-European
Organization for Research and Treatment of Cancer (NCI-
EORTC) [13]. Plasma quantitative assays were performed
by investigators blinded to the study endpoint. We have a
designated staff member who was tasked to build up the
prospective clinical database, including follow-up details, and
who was not aware of assay data. Assays were performed
by another research staff member who did not know the
clinical details of the specimen. The assay data of the bio-
marker, together with the clinical information, were then
combined and analyzed by an independent investigator.
Statistical Methods
The quantitative data of plasma transcript AA454543
RNA, AFP RNA, and serum AFP protein levels were con-
tinuous variables, and the data were modeled as categorical
variables in Kaplan-Meier and Cox regression analyses. The
Youden index (sensitivity + specificity1) [14] was employed
to determine the optimal cutoff point for prognosis prediction.
Other cutoff values, including themean and themedian, have
also been considered and examined. They were all able to
segregate patients with similar clinical implications. The
Youden index was employed to simultaneously maximize
the sensitivity and the specificity of the prediction. The
association of transcript AA454543 data, AFP data, and
tumor stage [15] with overall survival and disease-free sur-
vival was examined by multivariate Cox proportional hazards
regression with a forward stepwise selection procedure. All
statistical analyses were performed by a statistical software
(SPSS version 12.0 for Windows; SPSS, Inc., Chicago, IL).
Differences were considered significant when P < .05.
Results
Ribosomal 18S RNA was used as an endogenous quality
control for all assays, and 18S RNA was detectable in all
plasma specimens from HCC patients [84 of 84 (100%);
median = 29.92, range = 24.65–33.02]. 18S RNA data
indicated the RNA quality and integrity of plasma specimens.
Plasma transcript AA454543 RNA was detectable in the
majority of specimens from HCC patients (78 of 84; 93%),
with a wide data range (median = 14.84, range = 0–22.02).
The positive detection rates of transcript AA454543 in plasma
(current study) and liver cancer tissues [12] were similar,
reflecting the significance of circulating tumor nucleic acids.
Plasma AFP RNA was detectable only in a subset of HCC
patients (65 of 84; 77%), with a diverse data range (median =
12.43, range = 0–18.75). There was no correlation between
plasma RNA levels of transcript AA454543 and AFP (Pear-
son correlation = 0.035, P = .752). The positive detection
rate of plasma AFP RNA (current study) was comparable
to that of serum AFP in the literature, as AFP was only ex-
pressed in a subset of HCC tissues. The current data fur-
ther highlighted the importance of identifying novel tumor
markers with sensitivity and specificity comparable to or
better than those of AFP for liver cancer management.
To evaluate if a high plasma transcript AA454543 RNA
level in HCC patients is associated with poor prognosis, we
analyzed its level for overall survival. Kaplan-Meier plot
was used to examine the prediction power by the quantity
of plasma transcript AA454543. The patients were segre-
gated into low-plasma or high-plasma transcript AA454543
groups using the Youden index to determine the optimal
cutoff value. There were 64 patients in the low-plasma tran-
script AA454543 group (range = 0–16.37) and 20 patients in
the high-plasma transcript AA454543 group (range = 16.38–
22.02). By the plasma transcript AA454543 level alone,
patients with a high plasma transcript AA454543 level were
found to have poor overall survival (log-rank test, P < .01)
(Figure 1). The analysis was repeated based on the plasma
transcript AA454543 levels and tumor stages [15] of patients.
In early-stage (stages I and II) patients, a high plasma
transcript AA454543 level was associated with poor over-
all survival (log-rank test, P = .01). In late-stage (stages III
and IV) patients, a high plasma transcript AA454543 level
was also associated with poor overall survival (log-rank
test, P < .01).
AFP RNA levels were also examined to evaluate their
prediction power. The patients were segregated into low-
plasma or high-plasma AFP RNA groups using the Youden
index to determine the optimal cutoff value. There were 27 pa-
tients in the low-plasma AFP RNA group (range = 0–5.56)
and 57 patients in the high-plasma AFP RNA group (range =
5.57–18.75). By Kaplan-Meier analysis, patients with dif-
ferent plasma AFP RNA levels did not reveal significant dif-
ferences in overall survival (log-rank test, P = .88) (Figure 2).
AFP protein levels were also evaluated for association
with overall survival. Patients were segregated according to
AFP protein levels, and the optimal cutoff value was 99 ng/ml,
as determined by the Youden index. There were 36 patients
in the low-AFP protein group (range = 0–99 ng/ml) and
48 patients in the high-AFP protein group (range = 100–
1,043,700 ng/ml). By Kaplan-Meier analysis, patients with
high AFP protein levels revealed poor overall survival (log-
rank test, P = .03) (Figure 3). In early-stage patients, the
difference in AFP protein levels revealed no difference in
overall survival (log-rank test, P = .43). Nonetheless, high
AFP protein levels showed a significant association with
poor overall survival only in late-stage patients (log-rank
test, P < .01).
Cox regression analysis was employed to compare gene
data with tumor stage on the prediction for overall survival
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Neoplasia . Vol. 8, No. 9, 2006
(Table 2). By univariate Cox regression analysis, high plasma
transcript AA454543 RNA level [hazard ratio (HR) = 2.9; 95%
confidence interval (95% CI) = 1.4–6.3; P < .01], high AFP
protein level (HR = 2.4; 95% CI = 1.1–5.3; P = .04), and late
tumor stage (HR = 1.5; 95% CI = 1.1–2.2; P = .02) were
significantly associated with overall survival (Table 2). The
plasma AFP RNA level did not demonstrate an association
with overall survival (P = .88). By multivariate Cox regres-
sion analysis, high plasma transcript AA454543 level (HR =
4.8; 95%CI = 2.1–10.6;P < .01), AFP protein level (HR = 3.0;
95% CI = 1.3–6.8; P < .01), and late tumor stage (HR = 1.7;
95% CI = 1.2–2.5; P < .01) were found to be independent
prognostic factors for overall survival.
Other clinicopathological features that might influence
prognosis were also examined together with plasma transcript
Figure 1. Kaplan-Meier overall survival plot according to plasma transcript
AA454543 RNA levels. (A) All patients (log-rank test, P < .01). (B) Early-stage
(stages I and II) patients (log-rank test, P = .01). (C) Late-stage (stages III and
IV) patients (log-rank test, P < .01).
Figure 2. Kaplan-Meier overall survival plot according to plasma AFP RNA
levels in all patients (log-rank test, P = .88).
Figure 3. Kaplan-Meier overall survival plot according to serum AFP protein
levels. (A) All patients (log-rank test, P = .03). (B) Early-stage (stages I and II)
patients (log-rank test, P = .43). (C) Late-stage (stages III and IV) patients
(log-rank test, P < .01).
Table 2. Cox Regression Analyses for Overall Survival on Plasma Transcript
AA454543 RNA Level, Plasma AFP RNA Level, Serum AFP Protein Level,
and Tumor Stage.
Variables* Univariate Analysis Multivariate Analysis
HR (95% CI) P Adjusted HR
(95% CI)
P
Transcript AA454543y 2.9 (1.4–6.3) < .01 4.8 (2.1–10.6) < .01
AFP RNAy – .88 – –
AFP proteiny 2.4 (1.1–5.3) .04 3.0 (1.3–6.8) < .01
Tumor stagez 1.5 (1.1–2.2) .02 1.7 (1.2–2.5) < .01
*All data were modeled as categorical variables.
yFor plasma transcript AA454543 RNA, AFP RNA, and serum AFP protein
levels, the optimal cutoff value used to segregate patients was determined by
the Youden index.
zTumor stage according to the American Joint Committee on Cancer Staging
Manual [15].
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AA454543 data by multivariate Cox regression analysis
(Tables W1 and W2). A similar analysis in relation to disease-
free survival was performed (FiguresW1–W3). Irrespective of
the inclusion of other clinicopathological variables in multi-
variate Cox regression analyses, the same conclusion can
be drawn: plasma transcript AA454543 RNA level is an
independent risk factor for the prediction of overall survival
and disease-free survival.
To further investigate whether the quantitative mea-
surement of plasma RNA levels could serve as a diagnostic
tool for HCC, we compared the data obtained from HCC pa-
tients to those obtained from healthy individuals (n = 10)
and cirrhotic patients with no underlying HCC (n = 10)
(Figures W4 and W5). Concerning the plasma RNA levels
of ribosomal 18S, transcript AA454543, and AFP, the outliers
were all HCC patients. However, control and patient groups
revealed an overlap in data range. Thus, plasma RNA levels
of transcript AA454543 could provide prognostic informa-
tion on HCC patients, but preliminary analysis showed that
it would not be applicable for disease diagnosis with the
current experimental design.
Discussion
We have previously reported that a high level of transcript
AA454543 in tumor tissues is predictive of poor prognosis in
HCC patients [12]. In the current study, we showed that
plasma transcript AA454543 level could provide similar prog-
nostic information in both early-stage and late-stage HCC
patients. Conversely, plasma AFP RNA level revealed no
prognostic significance, and serum AFP protein level only
demonstrated prognostic information for late-stage patients,
but not for early-stage patients. Similar AFPprotein data have
been reported. In patients with large HCCs (> 5 cm), a high
AFP protein level was significantly associated with a lower
10-year overall survival, but AFP protein levels revealed no
association with overall survival in patients with small HCC
[16]. Thus, AFP protein level can generally be referred to as
a reliable marker only in the advanced stage of HCC, but not
in the early stage, and plasma AFP RNA level revealed no
prognostic information in the current study. The performance
of transcript AA454543 and AFP as plasma RNA target
was compared. Plasma AFP RNA was detectable only in a
subset of HCC patients (77%)—apositive rate comparable to
that of AFP proteins in the literature. However, plasma
transcript AA454543 was detectable in the majority of HCC
patients (93%)—a positive rate comparable to that of tran-
script AA454543 expression in HCC tissues (96 of 101; 95%)
[12]. Thus, transcript AA454543 would be an applicable
marker for the majority of HCC patients, whereas AFP (as
plasmaRNA target or serumprotein) would be an appropriate
marker only for a subgroup of HCC patients. Existing data
demonstrated that the performance of transcript AA454543
was better than that of AFP as plasma RNA target.
The quantitation of plasma transcript AA454543 for prog-
nosis prediction will encompass important clinical information
to stratify patients into different risk groups. Stratification is
even better than tumor staging because, among patients in
early tumor stage, further stratification into a subgroup of
patients whose survival rates are similar to late-tumor-stage
patients is possible. This helps to identify high-risk patients
who have a high plasma transcript AA454543 level in the
early tumor stage, as they may benefit from adjuvant therapy
after partial hepatectomy. Conversely, low-risk patients de-
veloping recurrence but with poor liver function may have
good prognosis if they undergo salvage liver transplantation
[17], even though they have large tumors or have been di-
agnosed at a late stage.
To further understand the significance of plasma RNA
levels, we have analyzed the clinicopathological features of
patients with different plasma RNA levels of transcript
AA454543 and AFP (data not shown). Other than the out-
comes of overall survival and disease-free survival, the
plasma RNA levels of AA454543 and AFP were not signifi-
cantly associated with tumor stage, tumor size, age, venous
infiltration, microsatellite nodules, tumor encapsulation, liver
cirrhosis, differentiation status (Edmondson-Steiner grade),
hepatitis B surface antigen (HBsAg) status, and intrahepatic
or extrahepatic recurrence. The exact mechanism of how
tumor RNA entered the circulation is unknown [1–3]; thus, its
clinicopathological significance is not clear. Nonetheless, the
higher transcript AA454543 levels in HCC tissues were
associated with aggressive tumor features [12]. As plasma
transcript AA454543 levels were a reflection of tumor levels,
they could provide prognostic information.
Earlier reports on circulating tumor contents were mostly
assays on circulating tumor cells, and controversial data on
diagnostic and prognostic values were presented [18–31].
Recently, extracellular-based assays (circulating DNA/RNA)
were found to be as efficacious as, or better than, cell-based
assays (circulating tumor cells) in the detection of pre-
neoplastic lesions and micrometastases [32]. Extracellular-
based assays demonstrated potential for broad clinical
applications because they allow automation and high-
throughput platforms, and are less prone to sampling errors
[2,32]. Furthermore, the relative proportion of tumor-derived
nucleic acids was reported to be higher in plasma than in
serum [33,34]. Thus, in the current study, we employed
quantitative measurements on plasma RNA rather than on
serum RNA. Exactly how RNA entered the circulation was
unknown [1–3]. RNA in apoptotic bodies was protected from
degradation in the circulation [35], and apoptosis was a
mechanism through which nucleic acids entered the circula-
tion [36]. Accordingly, it was speculated that circulating
nucleic acids might be released from the apoptotic cells of
the tumor mass. Alternatively, tumor cells were detached
from the tumor mass (process of metastasis), and some of
these circulating tumor cells underwent apoptosis because of
detachment stress in the bloodstream, and their contents
were released as circulating nucleic acids.
The quantitative assay of plasmaRNA is feasible for direct
clinical application as the test is not expensive (< US$30),
assays have automation platforms, and only 0.2 ml of plasma
(equivalent to 0.5 ml of whole blood) is needed. The assay, in
the form of a noninvasive blood test, can provide prognostic
information and is more practical than assays involving tissue
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specimens. The need for tissue specimens will make the test
less useful for clinical applications, as tissue specimens may
not be readily available: biopsies may have morbidity and
mortality consequences, and surgical specimens are avail-
able only after the operation. A simple blood test is therefore
more feasible.
The current data indicate, for the first time, that preoper-
ative plasma transcript AA454543 RNA level can predict
prognosis for HCC patients receiving curative partial hepa-
tectomy. To consolidate the current findings, we have initiated
a large-scale prospective study to examine, in parallel, other
factors/biomarkers that have reported associations with
cancer recurrence. This will enhance our understanding on
the relative importance of each factor/biomarker and the
formulation for accurate prognosis.
References
[1] Anker P, Mulcahy H, and Stroun M (2003). Circulating nucleic acids in
plasma and serum as a noninvasive investigation for cancer: time for
large-scale clinical studies? Int J Cancer 103, 149–152.
[2] Goessl C (2003). Diagnostic potential of circulating nucleic acids for
oncology. Expert Rev Mol Diagn 3, 431–442.
[3] Lo YM and Chiu RW (2004). The biology and diagnostic applications of
plasma RNA. Ann N Y Acad Sci 1022, 135–139.
[4] Silva JM, Dominguez G, Silva J, Garcia JM, Sanchez A, Rodriguez O,
Provencio M, Espana P, and Bonilla F (2001). Detection of epithelial
messenger RNA in the plasma of breast cancer patients is asso-
ciated with poor prognosis tumor characteristics. Clin Cancer Res 7,
2821–2825.
[5] Chen XQ, Bonnefoi H, Pelte MF, Lyautey J, Lederrey C, Movarekhi S,
Schaeffer P, Mulcahy HE, Meyer P, Stroun M, et al. (2000). Telomerase
RNA as a detection marker in the serum of breast cancer patients. Clin
Cancer Res 6, 3823–3826.
[6] Kopreski MS, Benko FA, Kwak LW, and Gocke CD (1999). Detection of
tumor messenger RNA in the serum of patients with malignant mela-
noma. Clin Cancer Res 5, 1961–1965.
[7] Lo KW, Lo YM, Leung SF, Tsang YS, Chan LY, Johnson PJ, Hjelm NM,
Lee JC, and Huang DP (1999). Analysis of cell-free Epstein-Barr virus
associated RNA in the plasma of patients with nasopharyngeal carci-
noma. Clin Chem 45 (8 Pt 1), 1292–1294.
[8] Novakovic S, Hocevar M, Zgajnar J, Besic N, and Stegel V (2004). De-
tection of telomerase RNA in the plasma of patients with breast cancer,
malignant melanoma or thyroid cancer. Oncol Rep 11, 245–252.
[9] Sueoka E, Sueoka N, Iwanaga K, Sato A, Suga K, Hayashi S,
Nagasawa K, and Nakachi K (2005). Detection of plasma hnRNP B1
mRNA, a new cancer biomarker, in lung cancer patients by quantitative
real-time polymerase chain reaction. Lung Cancer 48, 77–83.
[10] Wong SC, Lo SF, Cheung MT, Ng KO, Tse CW, Lai BS, Lee KC, and Lo
YM (2004). Quantification of plasma beta-catenin mRNA in colorectal
cancer and adenoma patients. Clin Cancer Res 10, 1613–1617.
[11] Chen X, Cheung ST, So S, Fan ST, Barry C, Higgins J, Lai KM, Ji J,
Dudoit S, Ng IO, et al. (2002). Gene expression patterns in human liver
cancers. Mol Biol Cell 13, 1929–1939.
[12] Cheung ST, Ho JC, Leung KL, Chen X, Fong DY, So S, and Fan ST
(2005). Transcript AA454543 is a novel prognostic marker for hepato-
cellular carcinoma after curative partial hepatectomy. Neoplasia 7,
91–98.
[13] McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, and Clark
GM (2005). Reporting recommendations for tumor marker prognostic
studies. J Clin Oncol 23, 9067–9072.
[14] Youden WJ (1950). Index for rating diagnostic tests. Cancer 3, 32–35.
[15] Liver (including intrahepatic bile duct) (2002). In American Joint Com-
mittee on Cancer Staging Manual. 6th Ed. Greene FL, Page DL,
Fleming ID, Fritz AG, Balch CM, Haller DG, and Morrow M (Eds).
Springer, New York, NY. pp 131–138.
[16] Peng SY, Chen WJ, Lai PL, Jeng YM, Sheu JC, and Hsu HC (2004).
High alpha-fetoprotein level correlates with high stage, early recurrence
and poor prognosis of hepatocellular carcinoma: significance of hepa-
titis virus infection, age, p53 and beta-catenin mutations. Int J Cancer
112, 44–50.
[17] Belghiti J, Cortes A, Abdalla EK, Regimbeau JM, Prakash K, Durand F,
Sommacale D, Dondero F, Lesurtel M, Sauvanet A, et al. (2003). Re-
section prior to liver transplantation for hepatocellular carcinoma. Ann
Surg 238, 885–892.
[18] Paterlini-Brechot P, Vona G, and Brechot C (2000). Circulating tu-
morous cells in patients with hepatocellular carcinoma. Clinical impact
and future directions. Semin Cancer Biol 10, 241–249.
[19] Matsumura M, Niwa Y, Kato N, Komatsu Y, Shiina S, Kawabe T,
Kawase T, Toyoshima H, Ihori M, Shiratori Y, et al. (1994). Detection
of alpha-fetoprotein mRNA, an indicator of hematogenous spreading
hepatocellular carcinoma, in the circulation: a possible predictor of
metastatic hepatocellular carcinoma. Hepatology 20, 1418–1425.
[20] Hillaire S, Barbu V, Boucher E, Moukhtar M, and Poupon R (1994).
Albumin messenger RNA as a marker of circulating hepatocytes in
hepatocellular carcinoma. Gastroenterology 106, 239–242.
[21] Kar S and Carr BI (1995). Detection of liver cells in peripheral blood of
patients with advanced-stage hepatocellular carcinoma. Hepatology 21,
403–407.
[22] Louha M, Poussin K, Ganne N, Zylberberg H, Nalpas B, Nicolet J,
Capron F, Soubrane O, Vons C, Pol S, et al. (1997). Spontaneous
and iatrogenic spreading of liver-derived cells into peripheral blood of
patients with primary liver cancer. Hepatology 26, 998–1005.
[23] Funaki NO, Tanaka J, Seto SI, Kasamatsu T, Kaido T, and Imamura M
(1997). Hematogenous spreading of hepatocellular carcinoma cells:
possible participation in recurrence in the liver. Hepatology 25,
564–568.
[24] Gion T, Taketomi A, Shimada M, Shirabe K, Hasegawa H, Takenaka K,
and Sugimachi K (1998). Perioperative change in albumin messenger
RNA levels in patients with hepatocellular carcinoma. Hepatology 28,
1663–1668.
[25] Matsumura M, Shiratori Y, Niwa Y, Tanaka T, Ogura K, Okudaira T,
Imamura M, Okano K, Shiina S, and Omata M (1999). Presence of
alpha-fetoprotein mRNA in blood correlates with outcome in patients
with hepatocellular carcinoma. J Hepatol 31, 332–339.
[26] Ijichi M, Takayama T, Matsumura M, Shiratori Y, Omata M, and
Makuuchi M (2002). Alpha-fetoprotein mRNA in the circulation as a
predictor of postsurgical recurrence of hepatocellular carcinoma: a pro-
spective study. Hepatology 35, 853–860.
[27] Wong IH, Lau WY, Leung T, Yeo W, and Johnson PJ (1999). Hematog-
enous dissemination of hepatocytes and tumor cells after surgical resec-
tion of hepatocellular carcinoma: a quantitative analysis.Clin Cancer Res
5, 4021–4027.
[28] Jeng KS, Sheen IS, and Tsai YC (2004). Circulating messenger RNA of
alpha-fetoprotein: a possible risk factor of recurrence after resection of
hepatocellular carcinoma. Arch Surg 139, 1055–1060.
[29] Lemoine A, Le Bricon T, Salvucci M, Azoulay D, Pham P, Raccuia J,
Bismuth H, and Debuire B (1997). Prospective evaluation of circulating
hepatocytes by alpha-fetoprotein mRNA in humans during liver surgery.
Ann Surg 226, 43–50.
[30] Gross-Goupil M, Saffroy R, Azoulay D, Precetti S, Emile JF, Delvart V,
Tindiliere F, Laurent A, Bellin MF, Bismuth H, et al. (2003). Real-time
quantification of AFP mRNA to assess hematogenous dissemination
after transarterial chemoembolization of hepatocellular carcinoma.
Ann Surg 238, 241–248.
[31] Kienle P, Weitz J, Klaes R, Koch M, Benner A, Lehnert T, Herfarth C,
and von Knebel Doeberitz M (2000). Detection of isolated disseminated
tumor cells in bone marrow and blood samples of patients with hepa-
tocellular carcinoma. Arch Surg 135, 213–218.
[32] Kopreski MS and Gocke CD (2000). Cellular- versus extracellular-
based assays. Comparing utility in DNA and RNA molecular marker
assessment. Ann N Y Acad Sci 906, 124–128.
[33] Sidransky D (2000). Circulating DNA. What we know and what we need
to learn. Ann N Y Acad Sci 906, 1–4.
[34] Tsui NB, Ng EK, and Lo YM (2002). Stability of endogenous and
added RNA in blood specimens, serum, and plasma. Clin Chem 48,
1647–1653.
[35] Hasselmann DO, Rappl G, Tilgen W, and Reinhold U (2001). Extra-
cellular tyrosinase mRNA within apoptotic bodies is protected from deg-
radation in human serum. Clin Chem 47, 1488–1489.
[36] Jahr S, Hentze H, Englisch S, Hardt D, Fackelmayer FO, Hesch RD,
and Knippers R (2001). DNA fragments in the blood plasma of cancer
patients: quantitations and evidence for their origin from apoptotic and
necrotic cells. Cancer Res 61, 1659–1665.
Neoplasia . Vol. 8, No. 9, 2006
Plasma RNA and Liver Cancer Prognosis Cheung et al. 701
Table W1. Multivariate Cox Regression Analyses for Overall Survival.
Variables* Adjusted HR (95% CI) P
Transcript AA454543y 8.9 (3.4–23.1) < .01
AFP proteiny 5.9 (2.3–15.3) < .01
Albuminz 0.2 (0.1–0.6) < .01
Multiple tumor nodules 2.4 (12.9) < .01
*All data were modeled as categorical variables. Insignificant variables with P
> .05 were not listed in the table, including AFP RNA data, tumor stage,
venous infiltration, histologic grade (Edmondson-Steiner grade), tumor size,
age, sex, cirrhosis, HBsAg, Child-Pugh classification, and bilirubin level.
yFor plasma transcript AA454543 RNA and serum AFP protein levels, the
optimal cutoff value used to segregate patients was determined by the
Youden index, as described in the text.
zFor serum albumin level, the optimal cutoff value (40.5 g/l) used to segregate
patients was determined by the Youden index.
Table W2. Multivariate Cox Regression Analyses for Disease-Free Survival.
Variables* Adjusted HR (95% CI) P
Transcript AA454543y 4.7 (2.2–10.5) < .01
Albuminz 0.5 (0.3–0.9) .03
Multiple tumor nodules 4.7 (2.5–8.9) < .01
Venous infiltration 3.5 (1.5–8.2) < .01
*All data were modeled as categorical variables. Insignificant variables with
P > .05 were not listed in the table, including AFP RNA data, serum AFP,
tumor stage, histologic grade (Edmondson-Steiner grade), tumor size, age,
sex, cirrhosis, HBsAg, Child-Pugh classification, and bilirubin level.
yFor plasma transcript AA454543 RNA level, the optimal cutoff value used
to segregate patients was determined by the Youden index, as described in
the text.
zFor serum albumin level, the optimal cutoff value (40.5 g/l) used to segregate
patients was determined by the Youden index.
Figure W1. Kaplan-Meier disease-free survival plot according to plasma
transcript AA454543 RNA levels. (A) All patients (log-rank test, P = .05). (B)
Early-stage (stages I and II) patients (log-rank test, P = .11). (C) Late-stage
(stages III and IV) patients (log-rank test, P < .01).
Figure W2. Kaplan-Meier disease-free survival plot according to plasma AFP
RNA levels in all patients (log-rank test, P = .86).
Figure W3. Kaplan-Meier disease-free survival plot according to serum AFP
protein levels. (A) All patients (log-rank test, P = .04). (B) Early-stage (stages I
and II) patients (log-rank test, P = .48). (C) Late-stage (stages III and IV)
patients (log-rank test, P = .05).
Figure W4. Plasma RNA levels in healthy individuals (n = 10), cirrhotic
patients without HCC (n = 10), and HCC patients (n = 84). The relative
quantitative value of plasma ribosomal 18S RNA was shown. Plasma
transcript AA454543 and AFP RNA showed similar distributions in controls
and patients. As control and patient groups revealed an overlap in the date
range, plasma transcript AA454543 could only provide prognostic information
to HCC patients, but would not be applicable for disease diagnosis.
Figure W5. Quantitative real-time RT-PCR curves. (A) Ribosomal 18S RNA.
(B) Transcript AA454543. (C) AFP.
